BTIG raised the firm’s price target on Organogenesis (ORGO) to $7 from $6 and keeps a Buy rating on the shares after its Q4 results. The firm is also adjusting its model to reflect forward rolled estimates and the company’s recent debt reduction, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO: